Notícias

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.

Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.

Intuitive Surgical's (ISRG) competitors face unique workflow challenges and real estate issues that

Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of "Crowding Out Competitors" is strategically smart.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Oppenheimer argues Ottava and Hugo pose no near-term threat to da Vinci

With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.

ISRG's premium valuation faces scrutiny as strong Q2 growth, higher margins and expanding robotic platforms support its 2026 outlook.

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]

Intuitive Surgical stock has had a difficult start to 2026, with the share price down 32.6% year to date, while the Discounted Cash Flow (DCF) intrinsic value estimate now points to a level that is broadly in line with where the market is pricing the company. The year to date decline of 32.6% raises the question of whether recent weakness is now fully reflected in the share price. Management commentary around durable demand for platforms like da Vinci 5 can support longer term cash flow...

Intuitive Surgical (NasdaqGS: ISRG) has approved amendments to its bylaws, updating shareholder voting rules, nomination processes, and procedural requirements in line with recent SEC universal proxy regulations. The revised bylaws clarify how proxy solicitations are conducted and what shareholders must disclose when putting forward director nominees or other proposals. The changes affect how investors can engage with the company on governance matters and may influence future proxy contests...

Intuitive Surgical is a leader in the surgical robotics space, with a large installed base and strong recurring revenues.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS reaching $2.80, exceeding expectations by $0.30. However, the stock declined as investors focused on concerns surrounding slowing domestic procedure growth. Medtronic (NYSE:MDT), meanwhile, continued its turnaround […]

Intuitive Surgical (ISRG), maker of the da Vinci surgical robot, has been one of the year's most punished large-cap healthcare names, down about 37% even as revenue keeps climbing. Analysts spent months cutting targets. Then one firm broke from the pack and told investors the fear had gone too far. ...

Intuitive Surgical (ISRG) has just overhauled its bylaws, reshaping how shareholders can nominate directors, submit proposals, and call special meetings. These governance changes arrive while the stock is still trading well below its recent highs. See our latest analysis for Intuitive Surgical. Over the last year, Intuitive Surgical’s share price return has been pressured, with the year to date share price return down 35.62% and the 90 day share price return down 20.28%, even though the 3...

Medtronic could finally be on the cusp of a long-awaited turnaround.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.

ISRG pairs durable platform demand and higher margin guidance with caution on softer U.S. procedure growth and deferred care.

Intuitive Surgical just posted its fifth consecutive earnings beat and management started buying back shares above current prices, yet the stock sits at a level that implies something far worse than a slowdown. One top analyst sees a near-double from here, and the math behind that call deserves a hard look.

Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.

Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.

Health policy has quietly become a stock-moving variable in 2026, and the figures are significant enough to matter. Approximately 2.6 million Americans discontinued ACA marketplace coverage this year after increased pandemic-era subsidies ended at the end of 2025, with health policy experts predicting that total enrollment would decrease to between 16.5 million and 17.5 million […]

The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.

Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.

J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.

ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.

CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.